Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Mar 27;62(4):e02432-17.
doi: 10.1128/AAC.02432-17. Print 2018 Apr.

Pharmacokinetics of Tedizolid in an Obese Patient after Bariatric Surgery

Matthieu Grégoire  1   2 , Julia Brochard Libois  3 , Denis Waast  4 , Benjamin Gaborit  3   5 , Marc Dauty  6 , Guillaume Deslandes  7 , Eric Dailly  7   8 , Sophie Touchais  4 , David Boutoille  3   5 , Nicolas Grégoire  9 , William Couet  9
Affiliations
Case Reports

Pharmacokinetics of Tedizolid in an Obese Patient after Bariatric Surgery

Matthieu Grégoire et al. Antimicrob Agents Chemother. .

Abstract

An obese woman was treated with oral tedizolid 200 mg once daily for pseudoarthrosis 10 years after Roux-en-Y bypass surgery. Total plasma peak concentration was 2.12 mg/liter 3 h after intake, and area under the concentration-time curve from 0 to 24 h (AUC0-24) was 28.3 mg/liter · h. The AUC0-24/MIC ratio for unbound concentrations and for sensitive Staphylococcus and Streptococcus strains was ≥10.8, higher than the target ratio of 3. These results support the use of tedizolid without adjustment after bariatric surgery.

Keywords: bariatric surgery; obesity; pharmacokinetics; tedizolid.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Pharmacokinetics of tedizolid in an obese patient treated with a 200-mg once-daily dose after gastric bypass surgery. Circles, total plasma concentrations; squares, unbound concentrations.
See this image and copyright information in PMC

References

    1. Pai MP. 2016. Pharmacokinetics of tedizolid in morbidly obese and covariate-matched nonobese adults. Antimicrob Agents Chemother 60:4585–4589. doi:10.1128/AAC.00682-16. - DOI - PMC - PubMed
    1. Flanagan S, Minassian SL, Passarell JA, Fiedler-Kelly J, Prokocimer P. 2017. Pharmacokinetics of tedizolid in obese and nonobese subjects. J Clin Pharmacol 57:1290–1294. doi:10.1002/jcph.928. - DOI - PubMed
    1. Hachon L, Declèves X, Faucher P, Carette C, Lloret-Linares C. 2017. RYGB and drug disposition: how to do better? Analysis of pharmacokinetic studies and recommendations for clinical practice. Obes Surg 27:1076–1090. - PubMed
    1. Hamilton R, Thai XC, Ameri D, Pai MP. 2013. Oral bioavailability of linezolid before and after Roux-en-Y gastric bypass surgery: is dose modification necessary in obese subjects? J Antimicrob Chemother 68:666–673. doi:10.1093/jac/dks431. - DOI - PubMed
    1. Yu H, Pan C, Xie Q, Zheng Y, Hu Y, Lin Y. 2016. Simultaneous determination of tedizolid and linezolid in rat plasma by ultra performance liquid chromatography tandem mass spectrometry and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 1011:94–98. doi:10.1016/j.jchromb.2015.12.056. - DOI - PubMed

Publication types